Scandion Oncology obtains approval from the Ethics Committee on Clinical Application for SCO-101 in patients with drug-resistant metastatic colorectal cancer

Scandion Oncology A/S ("Scandion Oncology") today announces that the company has received approval from the Ethics Committee regarding its first clinical trial for SCO-101 at hospitals in Denmark. The only change that the Ethics Committee requested was to include a one-page summary of the patient information sheet for review before the study could be started. With this approval, Scandion Oncology follows its objectives.

The release as fetched from its publisher. scandiononcology.com ↗